重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗前后银屑病患者血清脂联素水平的变化  

Effects of Recombinant human tumor necrosis factor-α receptor Ⅱ: IgG Fc fusion protein on serum adiponectin levels in psoriatic patients

作　　者：鹿洪艳 吕成志[1] 宋顺鹏[1] 

机构地区：[1]大连市皮肤病医院银屑病专科,辽宁大连116001

出　　处：《临床皮肤科杂志》2017年第6期391-394,共4页Journal of Clinical Dermatology

摘　　要：目的:研究分析注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(商品名,益赛普)对银屑病患者血清脂联素水平的影响。方法:将28例寻常性银屑病患者(银屑病组)及28例年龄、性别和体重指数(BMI)相匹配的健康志愿者(健康对照组)纳入研究,银屑病严重性评级指标采用银屑病皮损面积和严重程度指数(PASI)及体表受累面积(BSA)评分,所有患者均给予益赛普50 mg,皮下注射,每周1次。对所有银屑病患者治疗前、治疗后12周、24周与健康对照组的血清脂联素水平进行随访检测。结果:银屑病组血清脂联素水平较健康对照组明显降低,差异有统计学意义(P<0.05)。经过12周的益赛普治疗后,银屑病组血清脂联素水平较治疗前升高,但差异无统计学意义(P>0.05),经过24周的益赛普治疗后,银屑病组血清脂联素水平较治疗前及治疗12周后均有明显升高,差异有统计学意义(P<0.05),与健康对照组相比差异无统计学意义。结论:脂联素与银屑病的发病可能具有相关性,使用益赛普治疗银屑病,可降低银屑病患者代谢综合征的发生率。Objective： To study the changes in levels of serum adiponectin in psoriatic patients following the treatment with recombinant human tumor necrosis factor-α receptor Ⅱ： IgG Fe fusion protein（rhTNFR：Fc; Trade name： Etanercept）, and to explore the mechanism of psoriasis-associated metabolic syndrome and the benefit of Etanereept in reducing the incidence of metabolic syndrome while improving psoriasis. Methods： The 28 cases of psoriasis vulgaris and 28 cases of age, sex and BMI-matched healthy volunteers（healthy control group） were included in the study. The severity of psoriasis was assessed using psoriasis area and severity index（PASI） and body surface area（BSA）. All patients were subcutaneously injected with E- tanercept 50 mg, once weekly. The levels of serum adiponectin in psoriatic patients were assessed before, after 12- and 24- week treatment, meanwhile adiponectin levels were also measured in the controls. Results： The basal levels of adiponectin in psoriatic patients were significantly lower than that in the controls（P〈0.05）. 12-week treatment with Etanercept did not significantly alter serum adiponectin levels. Following 24 weeks of treatment, serum adiponectin levels were significantly higher in comparison to pretreatment and after 12-week treatment （P〈0.05）, but comparable to that in the controls. Conclusions： Adiponectin is closely associated with the development of psoriasis, and Etanercept may be able to reduce the incidence of metabolic syndrome in psoriatic patients.

关 键 词：益赛普 脂联素 银屑病 寻常性 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]